4.8 Article

Higd1a is a positive regulator of cytochrome c oxidase

Publisher

NATL ACAD SCIENCES
DOI: 10.1073/pnas.1419767112

Keywords

cytochrome c oxidase; oxidative phosphorylation; resonance Raman spectroscopy; ATP; oxygen

Funding

  1. Japan Society for the Promotion of Science
  2. Ministry of Health, Labor, and Welfare-Japan
  3. Ministry of Education, Culture, Sports, Science, and Technology-Japan
  4. Takeda Science Foundation,
  5. Japan Heart Foundation
  6. Japan Cardiovascular Research Foundation
  7. Japan Intractable Diseases Research Foundation
  8. Japan Foundation of Applied Enzymology
  9. Japan Medical Association
  10. Uehara Memorial Foundation
  11. Mochida Memorial Foundation
  12. Banyu Foundation
  13. Naito Foundation
  14. Inoue Foundation for Science, Osaka Medical Research foundation for intractable diseases
  15. Ichiro Kanehara Foundation
  16. Showa Houkoukai
  17. Grants-in-Aid for Scientific Research [24591096, 25109540, 26670402, 26291033, 26104532, 26253049, 25461119] Funding Source: KAKEN

Ask authors/readers for more resources

Cytochrome c oxidase (CcO) is the only enzyme that uses oxygen to produce a proton gradient for ATP production during mitochondrial oxidative phosphorylation. Although CcO activity increases in response to hypoxia, the underlying regulatory mechanism remains elusive. By screening for hypoxia-inducible genes in cardiomyocytes, we identified hypoxia inducible domain family, member 1A (Higd1a) as a positive regulator of CcO. Recombinant Higd1a directly integrated into highly purified CcO and increased its activity. Resonance Raman analysis revealed that Higd1a caused structural changes around heme a, the active center that drives the proton pump. Using a mitochondria-targeted ATP biosensor, we showed that knockdown of endogenous Higd1a reduced oxygen consumption and subsequent mitochondrial ATP synthesis, leading to increased cell death in response to hypoxia; all of these phenotypes were rescued by exogenous Higd1a. These results suggest that Higd1a is a previously unidentified regulatory component of CcO, and represents a therapeutic target for diseases associated with reduced CcO activity.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available